New hope for AML patients: experimental drug IPN60340 enters key trial
NCT ID NCT07623187
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part. The trial is double-blinded, so neither participants nor doctors know who gets IPN60340 or a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPN60340 (a biologic drug given by IV) plus azacitidine and venetoclax
What this could lead to
If it works, this could improve remission rates for people with acute myeloid leukemia who cannot handle strong chemotherapy.
What could go wrong
This is an early-to-mid-stage trial with 450 participants. The drug may not work better than placebo, and side effects from the combination could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••